Papp K - Search Results

1

Secukinumab in plaque psoriasis--results of two phase 3 trials.

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Langley RG, et al. Among authors: papp k. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9. N Engl J Med. 2014. PMID: 25007392 Free article. Clinical Trial.

2

Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.

Ho VC, Griffiths CE, Berth-Jones J, Papp KA, Vanaclocha F, Dauden E, Beard A, Puvanarajan L, Paul C. Ho VC, et al. Among authors: papp ka. J Am Acad Dermatol. 2001 Apr;44(4):643-51. doi: 10.1067/mjd.2001.112400. J Am Acad Dermatol. 2001. PMID: 11260540 Clinical Trial.

3

Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.

Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE Jr. Menter A, et al. J Drugs Dermatol. 2004 Jan-Feb;3(1):27-38. J Drugs Dermatol. 2004. PMID: 14964744 Clinical Trial.

4

Etanercept in psoriasis.

Papp KA. Papp KA. Expert Opin Pharmacother. 2004 Oct;5(10):2139-46. doi: 10.1517/14656566.5.10.2139. Expert Opin Pharmacother. 2004. PMID: 15461549 Review.

5

Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis.

Papp K, Staab D, Harper J, Potter P, Puig L, Ortonne JP, Molloy S, Barbier N, Paul C; Multicentre Investigator Study Group. Papp K, et al. Int J Dermatol. 2004 Dec;43(12):978-83. doi: 10.1111/j.1365-4632.2004.02121.x. Int J Dermatol. 2004. PMID: 15569038 Clinical Trial.

6

Efalizumab: Advancing psoriasis management with a novel, targeted T-cell modulator.

Papp KA. Papp KA. Drugs Today (Barc). 2004 Nov;40(11):889-99. doi: 10.1358/dot.2004.40.11.872578. Drugs Today (Barc). 2004. PMID: 15645002 Review.

7

Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004.

Guenther L, Langley RG, Shear NH, Bissonnette R, Ho V, Lynde C, Murray E, Papp K, Poulin Y, Zip C. Guenther L, et al. Among authors: papp k. J Cutan Med Surg. 2004 Sep-Oct;8(5):321-37. doi: 10.1007/s10227-005-0035-1. J Cutan Med Surg. 2004. PMID: 15868311

8

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.

Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L; Etanercept Psoriasis Study Group. Papp KA, et al. Br J Dermatol. 2005 Jun;152(6):1304-12. doi: 10.1111/j.1365-2133.2005.06688.x. Br J Dermatol. 2005. PMID: 15948997 Clinical Trial.

9

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.

Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE; EXPRESS study investigators. Reich K, et al. Among authors: papp k. Lancet. 2005 Oct 15-21;366(9494):1367-74. doi: 10.1016/S0140-6736(05)67566-6. Lancet. 2005. PMID: 16226614 Clinical Trial.

10

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R. Tyring S, et al. Among authors: papp k. Lancet. 2006 Jan 7;367(9504):29-35. doi: 10.1016/S0140-6736(05)67763-X. Lancet. 2006. PMID: 16399150 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

706 results

Search Page